文献速递泌尿男性生殖肿瘤

Capivasertib联合阿比特龙治疗PTEN缺陷型转移性激素敏感性前列腺癌:CAPItello-281 III期研究

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.
PubMed 文献 · Ann Oncol · 2025-10-19

CAPItello-281研究纳入PTEN缺陷型mHSPC患者,随机接受capivasertib或安慰剂联合阿比特龙及ADT。主要终点rPFS在capivasertib组显著改善(中位33.2 vs 25.7个月,HR 0.81,P=0.034),OS无显著差异。不良事件以腹泻、高血糖和皮疹常见。

要点

  • capivasertib联合阿比特龙较安慰剂显著改善PTEN缺陷型mHSPC的rPFS,中位延长7.5个月。
  • OS在总体研究人群中无显著获益(HR 0.90,P=0.401)。
  • PTEN缺失程度越高,安慰剂组rPFS越差,capivasertib组疗效一致。

核心结论

  • 在ADT背景下,capivasertib联合阿比特龙较安慰剂联合阿比特龙显著改善PTEN缺陷型mHSPC患者的rPFS。
  • PTEN缺陷型mHSPC患者可从PI3K/AKT和AR通路的双重阻断中获益。

研究设计与样本

  • CAPItello-281为III期随机研究(NCT04493853),PTEN缺陷型mHSPC患者按1:1随机接受capivasertib或安慰剂联合阿比特龙、泼尼松/泼尼松龙及ADT。
  • PTEN缺陷诊断标准为≥90%存活恶性肿瘤细胞无特异性胞质PTEN免疫组化染色。
  • 主要终点为研究者评估的rPFS,OS为关键次要终点。
  • 随机人群中共507例接受capivasertib联合阿比特龙,505例接受安慰剂联合阿比特龙。

主要发现

  • capivasertib联合阿比特龙组中位rPFS为33.2个月,安慰剂联合阿比特龙组为25.7个月(HR 0.81,95%CI 0.66-0.98,P=0.034)。
  • 总体研究人群中OS的HR为0.90(95%CI 0.71-1.15,P=0.401),数据成熟度26.4%。
  • 事后探索性分析显示,PTEN缺失cut-off提高至≥95%、≥99%和100%时,capivasertib组rPFS表现一致,而安慰剂组进行性变差。
  • capivasertib联合阿比特龙组最常见不良事件为腹泻(51.9% vs 安慰剂组8.0%)、高血糖(38.0% vs 12.9%)和皮疹(35.4% vs 7.0%)。
  • 与不良事件相关的死亡在capivasertib组报告36例(7.2%),安慰剂组26例(5.2%)。

关键数值与推荐

  • PTEN缺陷定义为≥90%存活恶性肿瘤细胞无特异性胞质PTEN免疫组化染色。
  • 在6003例有有效肿瘤检测结果的患者中,25.3%(1519/6003)为PTEN缺陷型。

临床怎么用

  • 对于PTEN缺陷型mHSPC患者,可考虑在ADT基础上采用capivasertib联合阿比特龙以改善rPFS。
  • 治疗期间需监测腹泻、高血糖和皮疹等不良事件。

局限性

  • OS数据尚未成熟,成熟度为26.4%,未显示显著获益。
  • PTEN cut-off阈值的事后探索性分析需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In metastatic hormone-sensitive prostate cancer (mHSPC), phosphatase and tensin homolog (PTEN) deficiency results in phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway activation, providing an independent proliferative drive, which cannot be suppressed by androgen receptor pathway inhibitors (ARPIs), resulting in worse outcomes. Dual inhibition of PI3K/AKT and AR pathways with capivasertib and abiraterone may delay progression and improve disease outcomes. PATIENTS AND METHODS: In CAPItello-281 (NCT04493853), patients with PTEN-deficient mHSPC (diagnostic cut-off: ≥90% viable malignant cells with no specific cytoplasmic PTEN immunohistochemistry staining) received capivasertib or placebo (1 : 1) plus abiraterone, prednisone/prednisolone, and androgen deprivation therapy (ADT). The primary endpoint was investigator-assessed radiographic progression-free survival (rPFS); overall survival (OS) was a key secondary endpoint. Post hoc exploratory subgroups at increasing PTEN cut-off thresholds were also assessed. RESULTS: 25.3% (1519/6003) of patients with valid tumor test results had PTEN-deficient tumors. In the randomized PTEN-deficient population, a statistically significant improvement in rPFS was observed with capivasertib plus abiraterone (n = 507, median 33.2 months) versus placebo plus abiraterone [n = 505, 25.7 months; hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.66-0.98, P = 0.034]. Post hoc rPFS analyses for loss of PTEN cut-offs of ≥95%, ≥99%, and 100% showed that the capivasertib plus abiraterone arm performed consistently across cut-offs, but the placebo plus abiraterone arm performed progressively worse as the cut-off for the degree of PTEN loss was increased, resulting in a numerically improved treatment effect. In the overall population studied, the HR for OS (26.4% maturity) was 0.90, 95% CI 0.71-1.15, P = 0.401. The most common adverse events (AEs) for capivasertib plus abiraterone were diarrhea (51.9%; 8.0% placebo plus abiraterone), hyperglycemia (38.0%; 12.9%), and rash (35.4%; 7.0%). Deaths associated with an AE were reported in 36 (7.2%) and 26 (5.2%) patients in the capivasertib plus abiraterone and placebo plus abiraterone arms, respectively. CONCLUSIONS: Capivasertib plus abiraterone improves rPFS versus placebo plus abiraterone in PTEN-deficient mHSPC, on a background of ADT, with a 7.5-month improvement in median rPFS. AE profile was consistent with that of the individual agents. Patients with PTEN-deficient mHSPC benefit from dual blockade of the PI3K/AKT and AR pathways with capivasertib plus abiraterone.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Fizazi K, Clarke NW, De Santis M, et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2025. PMID: 41120017. doi:10.1016/j.annonc.2025.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。